...
首页> 外文期刊>British Journal of Haematology >Follicular helper T-cells: Expanding roles in T-cell lymphoma and targets for treatment
【24h】

Follicular helper T-cells: Expanding roles in T-cell lymphoma and targets for treatment

机译:滤泡辅助性T细胞:在T细胞淋巴瘤和治疗靶标中的作用不断扩大

获取原文
获取原文并翻译 | 示例
           

摘要

Summary: Follicular helper T-cells (Tfh cells) are a subset of CD4+ T-cells that are essential for normal production of high affinity antibodies. Tfh cells characteristically produce IL21 and IL4 and show high expression of surface markers CXCR5, ICOS, PDCD1 (PD-1) and the chemokine CXCL13. In this review we will focus on the emerging links between Tfh cells and subtypes of T-cell non-Hodgkin lymphoma: angioimmunoblastic T-cell lymphoma (AITL) and ~20% of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) have surface marker features of Tfh cells and share a spectrum of genetic abnormalities. The recurrent genetic abnormalities associated with AITL include mutations in epigenetic modifiers such as TET2 and DNMT3A and the motility and adhesion gene, RHOA, is mutated in up to 70% of cases. ~20% of PTCL-NOS demonstrate RHOA mutations and have other characteristics suggesting an origin in Tfh cells. The recognition that specific genetic and surface markers are associated with malignant Tfh cells suggests that the next few years will bring major changes in diagnostic and treatment possibilities. For example, antibodies against IL21, PDCD1 and ICOS are already in clinical trials for autoimmune disease or other malignancies and antibodies against CXCL13 are in pre-clinical development.
机译:摘要:卵泡辅助性T细胞(Tfh细胞)是CD4 + T细胞的一个子集,对于正常产生高亲和力抗体至关重要。 Tfh细胞特征性地产生IL21和IL4,并显示表面标志物CXCR5,ICOS,PDCD1(PD-1)和趋化因子CXCL13的高表达。在这篇综述中,我们将重点关注Tfh细胞与T细胞非霍奇金淋巴瘤亚型之间的新兴联系:血管免疫母细胞性T细胞淋巴瘤(AITL)和约20%的周围T细胞淋巴瘤(未另作规定)(PTCL-NOS)具有Tfh细胞的表面标志物特征,并具有一系列遗传异常。与AITL相关的复发性遗传异常包括表观遗传修饰因子(如TET2和DNMT3A)的突变,并且运动和粘附基因RHOA在多达70%的病例中发生突变。约20%的PTCL-NOS表现出RHOA突变,并具有其他特征,提示其起源于Tfh细胞。特定遗传和表面标志物与恶性Tfh细胞相关的认识表明,未来几年将在诊断和治疗可能性方面带来重大变化。例如,针对IL21,PDCD1和ICOS的抗体已经在针对自身免疫性疾病或其他恶性肿瘤的临床试验中,针对CXCL13的抗体正在临床前开发中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号